Plasmin induces apoptosis of aortic valvular myofibroblasts

Journal of Pathology

Volumn 221, Issue 1, 2010, Pages 37-48

  Kochtebane, Najlah ^a,b   Choqueux, Christine ^a   Passefort, Stéphanie ^a   Nataf, Patrick ^c   Messika Zeitoun, David ^c   Bartagi, Aghleb ^b   Michel, Jean Baptiste ^a   Anglés Cano, Eduardo ^d   Jacob, Marie Paule ^a  

^a INSERM   (France)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d GIP CYCERON   (France)

Author keywords

Aortic valves; Apoptosis; Myofibroblasts; Plasminogen; Plasminogen activators

Indexed keywords

AGAR; AMILORIDE; AMINOCAPROIC ACID; FIBRIN; FIBRONECTIN; LIPOCORTIN 5; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; AORTA VALVE; AORTIC VALVULAR MYOFIBROBLAST; APOPTOSIS; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MYOFIBROBLAST; NICK END LABELING; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; TIME; WESTERN BLOTTING; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANOIKIS; AORTIC VALVE; APOPTOSIS; CELLS, CULTURED; FEMALE; FIBRINOLYSIN; FIBRINOLYSIS; FIBROBLASTS; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN; PLASMINOGEN ACTIVATORS; TISSUE CULTURE TECHNIQUES;

EID: 77951020329     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2681     Document Type: Article

References (38)

1. Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M, et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 2005; 26: 1333-1341. (Pubitemid 41435466)
2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368: 1005-1011. (Pubitemid 44353666)
3. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24: 1231-1243. (Pubitemid 36834640)
4. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21: 1220-1225. (Pubitemid 23106200)
5. Chan KL. Is aortic stenosis a preventable disease? J Am Coll Cardiol 2003; 42: 593-599.
6. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003; 57: 195-202.
7. Meilhac O, Ho-Tin-Noé B, Houard X, Philippe M, Michel JB, Anglés-Cano E. Pericellular plasmin induces smooth muscle cell anoikis. FASEB J 2003; 17: 1301-1303.
8. Chain D, Kreizman T, Shapira H, Shaltiel S. Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett 1991; 285: 251-256.
9. Zhang X, Chaudhry A, Chintala SK. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage. Mol Vis 2003; 9: 238-248. (Pubitemid 38097593)
10. Bonnefoy A, Legrand C. Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res 2000; 98: 323-332. (Pubitemid 30255936)
11. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-333. (Pubitemid 32663963)
12. Jenkins G. The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol 2008; 40: 1068-1078.
13. Michel JB. Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol 2003; 23: 2146-2154.
14. Rossignol P, Ho-Tin-Noé B, Vranckx R, Bouton MC, Meilhac O, Lijnen HR, et al. Protease nexin-1 inhibits plasminogen activationinduced apoptosis of adherent cells. J Biol Chem 2004; 279: 10346-10356. (Pubitemid 38372642)
15. Kapustin A, Shanahan CM. Targeting vascular calcification: softening-up a hard target. Curr Opin Pharmacol 2009; 9: 84-89.
16. Fleury V, Anglès-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 7630-7638.
17. Gaussem P, Grailhe P, Angles-Cano E. Sodium dodecyl sulfateinduced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor. J Biol Chem 1993; 268: 12150-12155. (Pubitemid 23168183)
18. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci 2001; 936: 226-236.
19. Reinartz J, Schäfer B, Batrla R, Klein CE, Kramer MD. Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res 1995; 220: 274-282.
20. Davis J, Wagner MR, Zhang W, Xu F, Van Nostrand WE. Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem 2003; 278: 19054-19061. (Pubitemid 36799292)
21. Reijerkerk A, Mosnier LO, Kranenburg O, Bouma BN, Carmeliet P, Drixler T, et al. Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol Cancer Res 2003; 1: 561-568. (Pubitemid 36706343)
22. Tulinsky A. The structures of domains of blood proteins. Thromb Haemost 1991; 66: 16-31
23. Mazzone A, Epistolato MC, Gianetti J, Castagnini M, Sassi C, Ceravolo R, et al. Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? Am J Clin Pathol 2006; 126: 494-502. (Pubitemid 44498498)
24. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptorbound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-12758. (Pubitemid 21907159)
25. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90: 844-853.
26. Salame MY, Samani NJ, Masood I, de Bono DP. Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis 2000; 152: 19-28.
27. Lau HK. Regulation of proteolytic enzymes and inhibitors in two smooth muscle cell phenotypes. Cardiovasc Res 1999; 43: 1049-1059.
28. Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-67. (Pubitemid 20223727)
29. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EK. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-1455.
30. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002; 17: 56-61.
31. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptorbound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-12758. (Pubitemid 21907159)
32. Fleury V, Lijnen HR, Anglés-Cano E. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem 1993; 268: 18554-18559.
33. Marshall JM, Brown AJ, Ponting CP. Conformational studies of human plasminogen and plasminogen fragments: evidence for a novel third conformation of plasminogen. Biochemistry 1994; 33: 3599-3606.
34. Christensen U, Mølgaard L. Positive co-operative binding at two weak lysine-binding sites governs the Glu-plasminogen conformational change. Biochem J 1992; 285: 419-425.
35. Mølgaard L, Ponting CP, Christensen U. Glycosylation at Asn-289 facilitates the ligand-induced conformational changes of human Glu-plasminogen. FEBS Lett 1997; 405: 363-368. (Pubitemid 27138506)
36. Isik FF, Gibran NS, Jang YC, Sandell L, Schwartz SM. Vitronectin decreases microvascular endothelial cell apoptosis. J Cell Physiol 1998; 175: 149-155. (Pubitemid 28140671)
37. Planus E, Barlovatz-Meimon G, Rogers RA, Bonavaud S, Ingber DE, Wang N. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J Cell Sci 1997; 110: 1091-1098. (Pubitemid 27232279)
38. Horowitz JC, Rogers DS, Simon RH, Sisson TH, Thannickal VJ. Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir Cell Mol Biol 2008; 38: 78-87.